Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DISP-10 · 1 trial · 4 indications
Graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) v6.0
Graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) v6.0
To select the Recommended Dose for Expansion (RDE) for Part 2
Confirmed complete response (CR) or partial response (PR), per RECIST v1.1
| Arm | Type | Description |
|---|---|---|
| DISP-10 | EXPERIMENTAL | Participants will receive DV-10 in combination with ide-cel. Lymphodepleting chemotherapy (fludarabine and cyclophosphamide) will be administered a few days prior to ide-cel. |
| Name | Type | Description |
|---|---|---|
| DISP-10 | BIOLOGICAL | Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce ide-cel. During ide-cel production, participants may receive bridging therapy for disease control per Investigator discretion. DV-10 administration will be followed by lymphodepleting chemotherapy (fludarabine and cyclophosphamide) and subsequent ide-cel administration. |
Key Inclusion Criteria: 1. Histologically confirmed advanced or metastatic esophageal, gastroesophageal junction, gastric adenocarcinoma, or colorectal adenocarcinoma 2. Measurable disease according to RECIST v1.1 and at least 1 additional site of disease amenable to biopsy 3. Eastern Cooperative O...
Top 20 of 81 competitors